Merrimack Pharmaceuticals, Inc.
MACK · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $191,750 | $154,985 | $52,421 | $92,188 |
| - Cash | $5,989 | $19,439 | $14,203 | $14,038 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $185,761 | $135,546 | $38,218 | $78,150 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$445 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | $1,007 | -$2,619 | -$2,760 | -$5,153 |
| % Margin | – | – | – | – |
| Net Income | -$1,181 | -$1,544 | -$2,455 | -$3,028 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.083 | -0.11 | -0.18 | -0.23 |
| % Growth | 24.9% | 38.9% | 21.7% | – |
| Operating Cash Flow | -$1,522 | -$1,742 | -$218 | -$4,625 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1,522 | -$1,742 | -$218 | -$4,625 |